{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-024338","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2025-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.940705+00:00","generated_at":"2026-05-17T12:21:08.551648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M","bullets":["Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.","Net loss from continuing operations $(3.2)M vs $(2.2)M in Q2 2024.","Adjusted EBITDA $(587,230) vs $(509,623) in prior year period.","Completed divestiture of majority stake in NAYA Therapeutics; retains minority position.","Launched telehealth and PRP therapy at Wisconsin clinic; received patent allowance for INVOcell device through 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-024338","json":"https://secwatch.observer/filing/0001641172-25-024338.json","markdown":"https://secwatch.observer/filing/0001641172-25-024338.md","text":"https://secwatch.observer/filing/0001641172-25-024338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225024338/0001641172-25-024338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000164117225024338/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:21:08.551648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}